• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Par launches advanced formulation of Megace ES

Article

Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.

Par launches advanced formulation of Megace ES

Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.